NOVARTINDPharmaceuticals
Novartis India Ltd — Profit & Loss Statement
₹672.25
+0.00%
Novartis India Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -1.03 Cr | 1.09 Cr | -0.66 Cr | -1.16 Cr | — |
| Tax Rate For Calcs | 0.23 | 0.31 | 0.10 | 0.03 | — |
| Normalized EBITDA | 137.92 Cr | 123.39 Cr | 129.48 Cr | 54.80 Cr | — |
| Total Unusual Items | -4.54 Cr | 3.55 Cr | -6.29 Cr | -44.14 Cr | — |
| Total Unusual Items Excluding Goodwill | -4.54 Cr | 3.55 Cr | -6.29 Cr | -44.14 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 100.90 Cr | 85.19 Cr | 103.36 Cr | -3.72 Cr | — |
| Reconciled Depreciation | 2.19 Cr | 2.61 Cr | 6.06 Cr | 9.65 Cr | — |
| Reconciled Cost Of Revenue | 205.72 Cr | 202.38 Cr | 204.62 Cr | 181.48 Cr | — |
| EBITDA | 133.38 Cr | 126.94 Cr | 123.19 Cr | 10.66 Cr | — |
| EBIT | 131.19 Cr | 124.33 Cr | 117.13 Cr | 1.01 Cr | — |
| Net Interest Income | 40.18 Cr | 53.85 Cr | 52.75 Cr | 16.40 Cr | — |
| Interest Expense | 0.77 Cr | 1.49 Cr | 1.75 Cr | 4.83 Cr | — |
| Interest Income | 40.95 Cr | 55.34 Cr | 54.50 Cr | 21.23 Cr | — |
| Normalized Income | 104.41 Cr | 82.73 Cr | 108.99 Cr | 39.26 Cr | — |
| Net Income From Continuing And Discontinued Operation | 100.90 Cr | 85.19 Cr | 103.36 Cr | -3.72 Cr | — |
| Total Expenses | 262.09 Cr | 268.78 Cr | 299.85 Cr | 370.17 Cr | — |
| Rent Expense Supplemental | 0.07 Cr | 0.11 Cr | 0.18 Cr | 0.36 Cr | — |
| Diluted NI Availto Com Stockholders | 100.90 Cr | 85.19 Cr | 103.36 Cr | -3.72 Cr | — |
| Net Income Common Stockholders | 100.90 Cr | 85.19 Cr | 103.36 Cr | -3.72 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 100.90 Cr | 85.19 Cr | 103.36 Cr | -3.72 Cr | — |
| Net Income Including Noncontrolling Interests | 100.90 Cr | 85.19 Cr | 103.36 Cr | -3.72 Cr | — |
| Net Income Continuous Operations | 100.90 Cr | 85.19 Cr | 103.36 Cr | -3.72 Cr | — |
| Tax Provision | 29.52 Cr | 37.65 Cr | 12.02 Cr | -0.10 Cr | — |
| Pretax Income | 130.42 Cr | 122.84 Cr | 115.38 Cr | -3.82 Cr | — |
| Other Non Operating Income Expenses | 0.90 Cr | 0.45 Cr | 0.72 Cr | 6.38 Cr | — |
| Special Income Charges | -4.54 Cr | 3.55 Cr | -6.29 Cr | -44.14 Cr | — |
| Other Special Charges | 4.71 Cr | -3.72 Cr | 5.92 Cr | -5.14 Cr | — |
| Write Off | -0.17 Cr | 0.17 Cr | 0.37 Cr | -0.36 Cr | — |
| Net Non Operating Interest Income Expense | 40.18 Cr | 53.85 Cr | 52.75 Cr | 16.40 Cr | — |
| Interest Expense Non Operating | 0.77 Cr | 1.49 Cr | 1.75 Cr | 4.83 Cr | — |
| Interest Income Non Operating | 40.95 Cr | 55.34 Cr | 54.50 Cr | 21.23 Cr | — |
| Operating Income | 94.17 Cr | 65.26 Cr | 69.26 Cr | 17.40 Cr | — |
| Operating Expense | 56.37 Cr | 66.40 Cr | 95.23 Cr | 188.69 Cr | — |
| Other Operating Expenses | 20.21 Cr | 18.67 Cr | 28.17 Cr | 45.05 Cr | — |
| Depreciation And Amortization In Income Statement | 2.19 Cr | 2.61 Cr | 6.06 Cr | 9.65 Cr | — |
| Depreciation Income Statement | 2.19 Cr | 2.61 Cr | 6.06 Cr | 9.65 Cr | — |
| Selling General And Administration | 14.74 Cr | 22.65 Cr | 34.40 Cr | 43.61 Cr | — |
| Selling And Marketing Expense | 10.58 Cr | 15.87 Cr | 27.98 Cr | 35.66 Cr | — |
| General And Administrative Expense | 4.16 Cr | 6.78 Cr | 6.42 Cr | 7.95 Cr | — |
| Rent And Landing Fees | 0.07 Cr | 0.11 Cr | 0.18 Cr | 0.36 Cr | — |
| Gross Profit | 150.54 Cr | 131.66 Cr | 164.49 Cr | 206.09 Cr | — |
| Cost Of Revenue | 205.72 Cr | 202.38 Cr | 204.62 Cr | 181.48 Cr | — |
| Total Revenue | 356.26 Cr | 334.04 Cr | 369.11 Cr | 387.57 Cr | — |
| Operating Revenue | 356.26 Cr | 334.04 Cr | 369.11 Cr | 387.57 Cr | — |
| Diluted Average Shares | — | — | 2.47 Cr | 2.47 Cr | 2.47 Cr |
| Basic Average Shares | — | — | 2.47 Cr | 2.47 Cr | 2.47 Cr |
| Diluted EPS | — | — | 41.86 | -1.51 | 8.46 |
| Basic EPS | — | — | 41.86 | -1.51 | 8.46 |
| Restructuring And Mergern Acquisition | — | — | 0.00 | 49.64 Cr | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Novartis India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.